THE IMPACT OF SEMAGLUTIDE ON HOSPITALIZATION AND HEALTHCARE COSTS IN ISRAEL
Author(s)
Ariel Israel, PhD, MD1, Moshe Leshno, MD, PhD2, Udi Moshel, BA3.
1Leumit Research Institute, Leumit Health Services, Tel Aviv, Israel, 2Coller school of Management and Faculty of Medical & Health Sciences, Tel-Aviv University, Tel Aviv, Israel, 3HEOR and Pricing, Market Access, Novo Nordisk, Tel Aviv, Israel.
1Leumit Research Institute, Leumit Health Services, Tel Aviv, Israel, 2Coller school of Management and Faculty of Medical & Health Sciences, Tel-Aviv University, Tel Aviv, Israel, 3HEOR and Pricing, Market Access, Novo Nordisk, Tel Aviv, Israel.
OBJECTIVES: This retrospective cohort study evaluates the healthcare cost and effectiveness of semaglutide in glycemic control, weight loss, and lipid profile improvement among patients with type 2 diabetes (T2D) in Israel
METHODS: The study utilized the electronic health records (EHR) of Leumit Health Services (LHS), identifying a cohort of 8,811 T2D patients who purchased semaglutide for at least 5 months between 2020 and 2023, and had BMI, serum glucose and HbA1c measurements in the 180 days prior to semaglutide treatment initiation. 6,359 of these patients were compared to a matched cohort of non-GLP-1 users in a 1:1 ratio, matched based on demographic, clinical, and comorbidity profiles using propensity score matching. The primary outcome was comparisons of healthcare costs and hospitalization days
RESULTS: The study showed a statistically significant reduction of 2.25 in hospitalization days and cost savings of 3,368 NIS per patient year for those treated with semaglutide
CONCLUSIONS: This study showed that using semaglutide for patients with T2D leads to cost savings in a relatively short period of time, the cost saving is mainly due to the improved clinical outcomes.
METHODS: The study utilized the electronic health records (EHR) of Leumit Health Services (LHS), identifying a cohort of 8,811 T2D patients who purchased semaglutide for at least 5 months between 2020 and 2023, and had BMI, serum glucose and HbA1c measurements in the 180 days prior to semaglutide treatment initiation. 6,359 of these patients were compared to a matched cohort of non-GLP-1 users in a 1:1 ratio, matched based on demographic, clinical, and comorbidity profiles using propensity score matching. The primary outcome was comparisons of healthcare costs and hospitalization days
RESULTS: The study showed a statistically significant reduction of 2.25 in hospitalization days and cost savings of 3,368 NIS per patient year for those treated with semaglutide
CONCLUSIONS: This study showed that using semaglutide for patients with T2D leads to cost savings in a relatively short period of time, the cost saving is mainly due to the improved clinical outcomes.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE334
Topic
Economic Evaluation, Health Service Delivery & Process of Care, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity)